Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation.
JCO Precis Oncol
; 6: e2100271, 2022 01.
Article
in En
| MEDLINE
| ID: mdl-35085006
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Benzamides
/
Protein Kinase Inhibitors
/
Indazoles
/
Neuroblastoma
Limits:
Humans
/
Infant
/
Male
Language:
En
Journal:
JCO Precis Oncol
Year:
2022
Document type:
Article
Affiliation country:
Suecia
Country of publication:
Estados Unidos